Form 4: Altimmune Director Wayne Pisano Granted Stock Options

Wayne Pisano, a director at Altimmune, Inc., was granted stock options for 34,900 shares on September 26, 2024, exercisable over the following 12 months.

Summary

• Wayne Pisano, a director of Altimmune, Inc., filed a Form 4 on September 30, 2024, reporting a transaction.
• On September 26, 2024, Pisano was granted stock options for 34,900 shares of Altimmune's common stock at an exercise price of $6.81 per share.
• The options vest in equal monthly installments over 12 months from the grant date, contingent upon continued service.
• Pisano also granted Vipin K. Garg and Andrew Shutterly power of attorney to handle SEC filings related to Altimmune securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) and power of attorney assignment, suggesting a neutral to slightly positive sentiment due to alignment of director's interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued contributions from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel. This grant aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Moderna and BioNTech also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 12 months is fairly standard, aligning with common industry practices for retaining talent.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential to profit from the company's success.

Key Dates